Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
Medical Physics
|
November 27, 2020
Important pharmacokinetic parameters for individualization of <sup>177</sup> Lu-PSMA therapy: A global sensitivity analysis for a physiologically-based pharmacokinetic model
Deni Hardiansyah, Peter Kletting, Nusrat J Begum, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
January 22, 2021
Mathematical Modeling of <i>In Vivo</i> Alpha Particle Generators and Chelator Stability
Nouran R R Zaid, Peter Kletting, Ambros J Beer, et al.
Plos One
|
September 10, 2016
Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides
Peter Kletting, Christiane Schuchardt, Harshad R Kulkarni, et al.
Medical Physics
|
September 11, 2012
Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy
Peter Kletting, Berthold Muller, Bahar Erentok, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 9, 2018
The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for <sup>177</sup>Lu-Labeled PSMA Peptides
Nusrat J Begum, Anne Thieme, Nina Eberhardt, et al.
EJNMMI Physics
|
December 14, 2021
A population-based method to determine the time-integrated activity in molecular radiotherapy
Deni Hardiansyah, Ade Riana, Peter Kletting, et al.
Nuclear Medicine and Biology
|
July 2, 2019
Modelling the internalisation process of prostate cancer cells for PSMA-specific ligands
Gordon Winter, Anja Vogt, Luis David Jiménez-Franco, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 12, 2018
Modeling and Predicting Tumor Response in Radioligand Therapy
Peter Kletting, Anne Thieme, Nina Eberhardt, et al.
Cancers
|
July 29, 2023
Optimization of Radiolabeling of a [<sup>90</sup>Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell Transplantation
Gordon Winter, Carmen Hamp-Goldstein, Gabriel Fischer, et al.
EJNMMI Research
|
October 1, 2022
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
Catherine Meyer, Vikas Prasad, Andreea Stuparu, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
Medical Physics
|
November 27, 2020
Important pharmacokinetic parameters for individualization of <sup>177</sup> Lu-PSMA therapy: A global sensitivity analysis for a physiologically-based pharmacokinetic model
Deni Hardiansyah, Peter Kletting, Nusrat J Begum, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
January 22, 2021
Mathematical Modeling of <i>In Vivo</i> Alpha Particle Generators and Chelator Stability
Nouran R R Zaid, Peter Kletting, Ambros J Beer, et al.
Plos One
|
September 10, 2016
Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides
Peter Kletting, Christiane Schuchardt, Harshad R Kulkarni, et al.
Medical Physics
|
September 11, 2012
Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy
Peter Kletting, Berthold Muller, Bahar Erentok, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 9, 2018
The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for <sup>177</sup>Lu-Labeled PSMA Peptides
Nusrat J Begum, Anne Thieme, Nina Eberhardt, et al.
EJNMMI Physics
|
December 14, 2021
A population-based method to determine the time-integrated activity in molecular radiotherapy
Deni Hardiansyah, Ade Riana, Peter Kletting, et al.
Nuclear Medicine and Biology
|
July 2, 2019
Modelling the internalisation process of prostate cancer cells for PSMA-specific ligands
Gordon Winter, Anja Vogt, Luis David Jiménez-Franco, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 12, 2018
Modeling and Predicting Tumor Response in Radioligand Therapy
Peter Kletting, Anne Thieme, Nina Eberhardt, et al.
Cancers
|
July 29, 2023
Optimization of Radiolabeling of a [<sup>90</sup>Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell Transplantation
Gordon Winter, Carmen Hamp-Goldstein, Gabriel Fischer, et al.
EJNMMI Research
|
October 1, 2022
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
Catherine Meyer, Vikas Prasad, Andreea Stuparu, et al.
Page
of 5